BioLife Solutions, Inc.
BLFSNASDAQHealthcare● Active
$26.10
$-0.55(-2.06%)
Market Cap$1.3B
P/E Ratio—
52W High$29.62
52W Low$17.86
BioLife Solutions, Inc.（BLFS）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BLFS · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.00M | ($20.18M) | ($66.43M) | ($139.81M) | ($7.63M) |
| Depreciation & Amort. | $0.00M | $5.49M | $12.29M | $16.47M | $12.87M |
| Stock-Based Comp. | $0.00M | $30.92M | $31.67M | $25.33M | $13.96M |
| Change in Working Capital | ($8.91M) | $0.23M | $1.47M | ($14.90M) | ($2.26M) |
| Net Cash from Operations | $20.11M | $8.43M | ($12.50M) | ($8.49M) | ($4.84M) |
| Investing Activities | |||||
| Capital Expenditure | ($9.48M) | ($3.23M) | ($6.38M) | ($10.38M) | ($8.38M) |
| Purchases of Investments | $0.00M | ($18.41M) | ($27.09M) | ($53.12M) | ($6.37M) |
| Sales of Investments | $0.00M | $21.92M | $56.17M | $8.92M | $6.37M |
| Net Cash from Investing | ($71.54M) | $58.30M | $17.84M | ($58.12M) | ($12.64M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($10.00M) | ($6.61M) | ($0.50M) | $17.84M | ($2.89M) |
| Net Cash from Financing | ($10.92M) | ($6.78M) | $10.59M | $16.32M | ($2.78M) |
| Free Cash Flow | |||||
| Free Cash Flow | $10.64M | $5.20M | ($18.88M) | ($18.87M) | ($13.22M) |
| FCF Margin %(computed) | 11.06% | 6.33% | -24.89% | -24.76% | -11.10% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解BioLife Solutions, Inc.
关于BioLife Solutions, Inc.（BLFS）现金流量表
BioLife Solutions, Inc. 2025财年经营活动现金流$0.02B，自由现金流$0.01B（FCF利润率11.06%），资本支出($0.01B)。
常见问题
BLFS · 4 问BioLife Solutions, Inc. 2025财年自由现金流$0.01B，同比up104.4%。
BLFS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10